{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination combined with anti‑PD‑L1 therapy improves tumor control in mouse models.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Mouse model results may not directly translate to human clinical outcomes."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination markedly raises the tumor type I interferon response score.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
          "line_ref": "L31"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "The interferon score is a normalized metric and its clinical relevance is not fully established."
    },
    {
      "claim_id": "C03",
      "claim": "Patients previously vaccinated with SARS‑CoV‑2 mRNA vaccines show improved survival when treated with immune checkpoint inhibitors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p‑value | p=0.01 | N/A",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non‑randomized, so confounding factors may influence the observed survival benefit."
    },
    {
      "claim_id": "C04",
      "claim": "Blocking type I interferon signaling with anti‑IFNAR1 eliminates the sensitization effect of mRNA vaccination.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti‑IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Interferon‑associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "The blockade experiments were performed in preclinical models; human relevance requires further validation."
    }
  ]
}